Patient was pregnant or a nursing mother

Patient had abused drugs or alcohol within 12 months prior to entering the study

Patient had a history of cardiovascular disease

Patient had clinically significant Electrocardiography (ECG) abnormality

Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening

Patient received treatment with an investigational device or compound within 30 days of the study start

Patient typically suffered from less then 1 or more than 8 attacks of migraine per month

Patient had difficulty in distinguishing his/her migraine attacks from tension or interval headaches

Patient had hypersensitivity to sumatriptan

Patient had participated in any previous study involving rizatriptan

Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)